Summary of Study ST003287
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002039. The data can be accessed directly via it's Project DOI: 10.21228/M8253C This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST003287 |
| Study Title | Metabolic profiling and synergistic therapeutic strategies unveil the cytotoxic potential of selenium-chrysin (SeChry) in NSCLC cells |
| Study Summary | Lung cancer ranks as the predominant cause of cancer-related mortalities on a global scale. Despite progress in therapeutic interventions, encompassing surgical procedures, radiation, chemotherapy, targeted therapies and immunotherapy, the overall prognosis remains unfavorable. Imbalances in redox equilibrium and disrupted redox signaling, common traits in tumors, play crucial roles in malignant progression and treatment resistance. Cancer cells, often characterized by persistent high levels of ROS resulting from genetic, metabolic, and microenvironmental alterations, counterbalance this by enhancing their antioxidant capacity. Cysteine availability emerges as a critical factor in chemoresistance, shaping the survival dynamics of non-small cell lung cancer (NSCLC) cells. Selenium-chrysin (SeChry) was disclosed as a modulator of cysteine intracellular availability. This study comprehensively characterizes the metabolism of SeChry in NSCLC. SeChry treatment induces notable metabolic shifts, particularly in selenocompounds metabolism, impacting crucial pathways such as glycolysis, gluconeogenesis, the tricarboxylic acid (TCA) cycle, and amino acid metabolism. Additionally, SeChry affects the levels of key metabolites such as acetate, lactate, glucose, and amino acids, contributing to disruptions in redox homeostasis and cellular biosynthesis. |
| Institute | ITQB NOVA |
| Last Name | Gonçalves |
| First Name | Luís |
| Address | Avenida Republica |
| lgafeira@itqb.unl.pt | |
| Phone | 214469464 |
| Submit Date | 2024-06-28 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | fid |
| Analysis Type Detail | NMR |
| Release Date | 2024-07-22 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR002039 |
| Project DOI: | doi: 10.21228/M8253C |
| Project Title: | Metabolic profiling and synergistic therapeutic strategies unveil the cytotoxic potential of selenium-chrysin (SeChry) in NSCLC cells |
| Project Summary: | Lung cancer ranks as the predominant cause of cancer-related mortalities on a global scale. Despite progress in therapeutic interventions, encompassing surgical procedures, radiation, chemotherapy, targeted therapies and immunotherapy, the overall prognosis remains unfavorable. Imbalances in redox equilibrium and disrupted redox signaling, common traits in tumors, play crucial roles in malignant progression and treatment resistance. Cancer cells, often characterized by persistent high levels of ROS resulting from genetic, metabolic, and microenvironmental alterations, counterbalance this by enhancing their antioxidant capacity. Cysteine availability emerges as a critical factor in chemoresistance, shaping the survival dynamics of non-small cell lung cancer (NSCLC) cells. Selenium-chrysin (SeChry) was disclosed as a modulator of cysteine intracellular availability. This study comprehensively characterizes the metabolism of SeChry in NSCLC. SeChry treatment induces notable metabolic shifts, particularly in selenocompounds metabolism, impacting crucial pathways such as glycolysis, gluconeogenesis, the tricarboxylic acid (TCA) cycle, and amino acid metabolism. Additionally, SeChry affects the levels of key metabolites such as acetate, lactate, glucose, and amino acids, contributing to disruptions in redox homeostasis and cellular biosynthesis. |
| Institute: | ITQB NOVA |
| Last Name: | Gonçalves |
| First Name: | Luís |
| Address: | Avenida Republica, Oeiras, Not USCanada, 2780-157 Oeiras, Portugal |
| Email: | lgafeira@itqb.unl.pt |
| Phone: | 214469464 |
Subject:
| Subject ID: | SU003407 |
| Subject Type: | Cultured cells |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
Factors:
Subject type: Cultured cells; Subject species: Homo sapiens (Factor headings shown in green)
| mb_sample_id | local_sample_id | Sample source | Cell Line | Condition |
|---|---|---|---|---|
| SA356301 | AH_aq_A7_230607 | Non-small cell lung cancer cells | A549 | Control |
| SA356302 | AH_aq_A8_230607 | Non-small cell lung cancer cells | A549 | Control |
| SA356303 | AH_aq_A2_230607 | Non-small cell lung cancer cells | A549 | SeChry |
| SA356304 | AH_aq_A1_230607 | Non-small cell lung cancer cells | A549 | SeChry |
| SA356305 | AH_aq_A6_230607 | Non-small cell lung cancer cells | A549 | SeChry |
| SA356306 | AH_aq_A3_230607 | Non-small cell lung cancer cells | A549 | SeChry |
| SA356307 | AH_aq_A4_230607 | Non-small cell lung cancer cells | A549 | SeChry |
| SA356308 | AH_aq_A5_230607 | Non-small cell lung cancer cells | A549 | SeChry |
| SA356309 | AH_aq_H8_230607 | Non-small cell lung cancer cells | H292 | Control |
| SA356310 | AH_aq_H7_230607 | Non-small cell lung cancer cells | H292 | Control |
| SA356311 | AH_aq_H3_230607 | Non-small cell lung cancer cells | H292 | SeChry |
| SA356312 | AH_aq_H5_230607 | Non-small cell lung cancer cells | H292 | SeChry |
| SA356313 | AH_aq_H6_230607 | Non-small cell lung cancer cells | H292 | SeChry |
| SA356314 | AH_aq_H2_230607 | Non-small cell lung cancer cells | H292 | SeChry |
| SA356315 | AH_aq_H1_230607 | Non-small cell lung cancer cells | H292 | SeChry |
| SA356316 | AH_aq_H4_230607 | Non-small cell lung cancer cells | H292 | SeChry |
| SA356317 | AH_aq_P7_230607 | Non-small cell lung cancer cells | PC9 | Control |
| SA356318 | AH_aq_P8_230607 | Non-small cell lung cancer cells | PC9 | Control |
| SA356319 | AH_aq_P1_230607 | Non-small cell lung cancer cells | PC9 | SeChry |
| SA356320 | AH_aq_P4_230607 | Non-small cell lung cancer cells | PC9 | SeChry |
| SA356321 | AH_aq_P5_230607 | Non-small cell lung cancer cells | PC9 | SeChry |
| SA356322 | AH_aq_P6_230607 | Non-small cell lung cancer cells | PC9 | SeChry |
| Showing results 1 to 22 of 22 |
Collection:
| Collection ID: | CO003400 |
| Collection Summary: | Cells were plated in 175 cm2 T-Flasks: H292 (1.5 × 107 cells/flask); A549 (2 × 107 cells/flask), and PC-9 (2.5 × 107 cells/flask) and exposed to control conditions or SeChry for 24 h. The cells were cultured in Dulbecco’s Modified Eagle’s Medium 1× (DMEM) (41965-039, Gibco, Life Technologies) supplemented with 10% fetal bovine serum (FBS; S 0615, Merck), 1% Antibiotic-Antimycotic (AA; P06-07300, PAN Biotech) and 50 μg/mL Gentamicin (15750-060, Gibco, Life Technologies). H1975, H522 and H596 were cultured in RPMI 1640 (BE12-167F, Lonza) supplemented with 0.58 g/L of L-glutamine, 1% FBS (S 0615, Merck) and 1% antibiotic-antimycotic (AA) (P06-07300, PAN Biotech). Cells were maintained at 37ºC in a humidified environment with 5% CO2. Cells were cultured until an optical confluence of 75–100% and detachment was performed with 0.05% trypsin-EDTA 1× (25300-054, Invitrogen). Before any in vitro experiment, cells were synchronized under starvation (FBS-free culture medium) overnight. |
| Sample Type: | Non-small cell lung cancer cell lines |
Treatment:
| Treatment ID: | TR003416 |
| Treatment Summary: | Cells were kept in control conditions or exposed to SeChry. The concentrations of SeChry for each cell line were chosen according to the previously determined half-maximum effective concentrations (EC50). |
Sample Preparation:
| Sampleprep ID: | SP003414 |
| Sampleprep Summary: | Culture media (supernatant) was collected and stored at -80 °C. Cell methanol/chloroform/water extracts were performed to separate the aqueous (methanol/water) and organic (chloroform) phases. |
Analysis:
| Analysis ID: | AN005384 |
| Analysis Type: | NMR |
| Analysis Protocol File: | LG_NSCLC_SeChry_protocol.txt |
| Num Factors: | 6 |
| Num Metabolites: | 46 |
| Units: | nanomoles |
NMR:
| NMR ID: | NM000286 |
| Analysis ID: | AN005384 |
| Instrument Name: | Bruker Avance II+ 800 MHz |
| Instrument Type: | FT-NMR |
| NMR Experiment Type: | 1D-1H |
| Spectrometer Frequency: | 800 MHz |
| NMR Probe: | 5 mm TCI cryoprobe |
| NMR Tube Size: | 5 mm |
